PATENT CLAIM ANALYSIS

Application Number: 15948303
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "093710"]

Abstract:
The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

Claim (Index 36):
A method of producing one or more compositions comprising human T cells which express a heterologous ligand binding domain or a heterologous receptor other than a T cell receptor (TCR), wherein said human T cells are derived from primary human T cells and wherein said method comprises: (i) obtaining one or more compositions comprising isolated primary human T cells, each of said compositions being comprised of primary human T cells isolated from at least one human donor; (ii) modifying the primary human T cells comprised in said one or more compositions comprising primary human T cells in order to functionally impair or reduce expression of one or more components of the TCR complex endogenously expressed by said human primary T cells; (iii) further modifying the primary human T cells in the one or more compositions comprising human T cells by introducing a nucleic acid which encodes a desired ligand binding domain or a desired receptor, wherein said ligand binding domain and receptor do not comprise a TCR; thereby producing one or more compositions comprising human T cells which express at least one desired ligand binding domain or desired receptor and further wherein one or more components of the TCR complex endogenously expressed by said human primary T cells is functionally impaired or the expression of one or more components of the TCR complex endogenously expressed by said human primary T cells is reduced.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 91.0
- Lexical Diversity: 2.4898
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14676028', '13459664', '15815261', '15383717', '15815197']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7089410471871664
- 35 USC 102 Novelty (BERT): 0.609538169003907
- Combined Prediction Score: 0.6990007593688405
- Mean Citation Score: 503.10232800000006
- Max Citation Score: 535.5146
- Similarity Product: 494.35494215472926

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test